ChIP–qPCR analyses of the chromatin-binding levels of the aforementioned CTCF variants for cancer mutations indicated significantly reduced binding at both the C-MYC and b-globin loci (Figures 4C and 4D). This evidence concerns the gene CTCF and cancer.